Volume 45, Issue 2 (6-2021)                   Research in Medicine 2021, 45(2): 50-54 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Gholami P, Bagheralmoosavi S, Kian Ersi S, Hojjat-Farsangi M, Salari S, Yaghmaie M, et al . Placental-specific protein 1 (PLAC1) gene expression profile in new diagnosed Chronic myeloid leukemia (CML) and Chronic lymphocytic leukemia (CLL) patients. Research in Medicine. 2021; 45 (2) :50-54
URL: http://pejouhesh.sbmu.ac.ir/article-1-2170-en.html
Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran , msshabani@yahoo.com
Abstract:   (1322 Views)
Purpose: Placenta-specific protein 1 (PLAC1) is one of the members of cancer-testis antigens family that has limited expression in normal tissue, but is upregulated in a variety of malignant tissues. Considering the lack of studies on the expression of FCRL1 in CML and CLL, the current study was conducted to examine the expression pattern of PLAC1 gene in these leukemias. 
Materials and Methods: Fresh peripheral blood samples were collected from 6 CML and 10 CLL patients. In addition, peripheral blood samples of 10 healthy individuals were collected in EDTA as control group. All patients and healthy individuals signed a consent letter before sampling. The mononuclear cells were separated using ficoll-hypaque gradient centrifugation. Isolated mononuclear cells were used for RNA extraction and cDNA synthesis using RT-PCR method. Then, PLAC1 transcript expression in comparison to GAPDH were detected via Real-Time PCR. The statistical analyses were performed using chi-square test in SPSS.
Results: All 10 normal samples were negative for PLAC1. The PLAC1 expression was found to be statistically different in CML group (4 out of 6 cases) compared with that in the normal group (Pvalue = 0.000). However, CLL revealed no significant difference compared to normal individuals for PLAC1 expression (P Value = 0.648). In a significant percentage of CML patients, PLAC1 expression was positive but in CLL patients PLAC1, transcript expression was not evident. 
Conclusion: It seems that PLAC1 could potentially be proposed as a biomarker in CML to aid in the diagnosis, prognosis, and treatment in the future.
Full-Text [PDF 591 kb]   (244 Downloads)    
Type of Study: Original | Subject: Hematology
Received: 2020/01/18 | Accepted: 2020/09/15 | Published: 2021/11/29

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This Journal is licensed under a Creative Commons Attribution 4.0 International License  | Research in Medicine

Designed & Developed by : Yektaweb